hexamethylene bisacetamide has been researched along with Glioma in 4 studies
N,N'-diacetyl-1,6-diaminohexane: chemical name obtained from Acta Biol Hung 1990;41(1-3):199-208
Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The modulation effects of hexamethylene bisacetamide (HMBA), a differentiation-inducing agent, on growth and differentiation of cells from human malignant glioma cell line SHG-44 were studied." | 7.69 | Modulation effects of hexamethylene bisacetamide on growth and differentiation of cultured human malignant glioma cells. ( Du, ZW; Huang, Q; Li, XN, 1996) |
| "Hexamethylene bisacetamide (HMBA)-induced growth inhibition and differentiation of the rat C6 glioma cell line were found to be accompanied by down-regulation of the constitutively expressed fra-1 gene." | 3.72 | Overexpression of the immediate early gene fra-1 inhibits proliferation, induces apoptosis, and reduces tumourigenicity of c6 glioma cells. ( Shaikh, SA; Shirsat, NV, 2003) |
| "The modulation effects of hexamethylene bisacetamide (HMBA), a differentiation-inducing agent, on growth and differentiation of cells from human malignant glioma cell line SHG-44 were studied." | 3.69 | Modulation effects of hexamethylene bisacetamide on growth and differentiation of cultured human malignant glioma cells. ( Du, ZW; Huang, Q; Li, XN, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Funck-Brentano, E | 1 |
| Vizlin-Hodzic, D | 1 |
| Nilsson, JA | 1 |
| Nilsson, LM | 1 |
| Shirsat, NV | 2 |
| Shaikh, SA | 1 |
| Li, XN | 1 |
| Du, ZW | 1 |
| Huang, Q | 1 |
| Kayal, JJ | 1 |
| Shaikh, S | 1 |
| Mehta, A | 1 |
4 other studies available for hexamethylene bisacetamide and Glioma
| Article | Year |
|---|---|
BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant glioma.
Topics: Acetamides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2021 |
Overexpression of the immediate early gene fra-1 inhibits proliferation, induces apoptosis, and reduces tumourigenicity of c6 glioma cells.
Topics: Acetamides; Animals; Antineoplastic Agents; Apoptosis; Astrocytoma; Brain Neoplasms; Bucladesine; Ce | 2003 |
Modulation effects of hexamethylene bisacetamide on growth and differentiation of cultured human malignant glioma cells.
Topics: Acetamides; Adult; Antineoplastic Agents; Brain Neoplasms; Cell Differentiation; Cell Line; Dose-Res | 1996 |
Growth inhibition and differentiation of C6 glioma cells on treatment with hmba.
Topics: Acetamides; Antineoplastic Agents; Brain Neoplasms; Cell Cycle; Cell Differentiation; Cell Division; | 2001 |